With two approved drugs and close to 300 clinical / preclinical product candidates, the bispecific antibody

With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
 
To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this link
 
The USD 6.9 billion financial opportunity (by 2030) within the bispecific antibody therapeutics market has been analyzed across the following segments:
Therapeutic Area
  • Autoimmune Disorders
  • Eye Disorders
  • Genetic Disorders
  • Hematological Malignancies
  • Infectious Diseases
  • Inflammatory Disorders
  • Skin Disorders
Mechanism of Action
  • Cytokines Retargeting / Neutralization
  • Dual Ligands Blocking
  • T-cell Retargeting / Activation
  • Others
Target Antigens
  • CD3 x CD19
  • CD30 x CD16A
  • Factor IXa x Factor X
  • IL-1α x IL-1β
  • IL-13 x IL-4
  • IL-17A x Albumin
  • IL-17A x IL-17F
  • Psl x PcrV
  • VEGF-A x ANG2
  • Others
Antibody Formats
  • Asymmetric
  • Fragments
  • Symmetric
  • Others
Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
 
The Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain: 
  • Amgen
  • Ablynx
  • AbbVie
  • Affibody
  • Affimed
  • Alphamab
  • AstraZeneca
  • Avillion
  • Chugai Pharmaceuticals
  • Eddingpharm
  • GSK
  • Merck
  • Merus
  • Roche
  • Regeneron Pharmaceuticals
  • Taisho Pharmaceuticals
  • Zymeworks
 
Table of Contents
 
1. Preface

2. Executive Summary

3. Introduction


4. Market Overview


5. Bispecific Antibody Therapeutics: Technology Platforms


6. Drug Profiles


7. Key Insights


8. Benchmark Analysis: Big Pharma Players


9. Partnerships and Collaborations


10. Contract Services for Bispecific Antibody Therapeutics


11. Clinical Trial Analysis


12. Case Study: Regulatory Guidelines for Bispecific Antibodies


13. Case Study: Promotional / Marketing Strategies


14. SWOT Analysis
15. Market Forecast and Opportunity Analysis
16. Concluding Remarks
17. Executive Insights
 
18. Appendix 1: Tabulated Data
 
19. Appendix 2: List of Companies and Organizations
 
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
 
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]

You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
415 Posts

Made with by Mamby